Rallybio Corporation
RLYB
$0.3026
$0.00170.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 38.00K | 299.00K | 299.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.00K | 299.00K | 299.00K | -- | -- |
| Cost of Revenue | 7.39M | 8.24M | 12.95M | -- | 15.92M |
| Gross Profit | -7.35M | -7.94M | -12.65M | -- | -15.92M |
| SG&A Expenses | 4.26M | 4.13M | 4.39M | 5.55M | 5.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.65M | 12.37M | 17.33M | 16.49M | 21.11M |
| Operating Income | -11.61M | -12.07M | -17.04M | -16.49M | -21.11M |
| Income Before Tax | -11.04M | -11.47M | -16.24M | -19.03M | -20.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.04M | -11.47M | -16.24M | -19.03M | -20.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.04M | -11.47M | -16.24M | -19.03M | -20.24M |
| EBIT | -11.61M | -12.07M | -17.04M | -16.49M | -21.11M |
| EBITDA | -11.58M | -12.03M | -17.00M | -16.45M | -21.08M |
| EPS Basic | -0.25 | -0.26 | -0.37 | -0.47 | -0.50 |
| Normalized Basic EPS | -0.15 | -0.16 | -0.23 | -0.24 | -0.31 |
| EPS Diluted | -0.25 | -0.26 | -0.37 | -0.47 | -0.50 |
| Normalized Diluted EPS | -0.15 | -0.16 | -0.23 | -0.24 | -0.31 |
| Average Basic Shares Outstanding | 44.66M | 44.59M | 44.13M | 40.77M | 40.64M |
| Average Diluted Shares Outstanding | 44.66M | 44.59M | 44.13M | 40.77M | 40.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |